Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
15.56
+0.31 (2.03%)
Feb 21, 2025, 4:00 PM EST - Market closed
Prothena Corporation Revenue
In the year 2024, Prothena Corporation had annual revenue of $135.16M with 47.92% growth. Prothena Corporation had revenue of $2.12M in the quarter ending December 31, 2024, with 571.84% growth.
Revenue (ttm)
$135.16M
Revenue Growth
+47.92%
P/S Ratio
6.19
Revenue / Employee
$781,254
Employees
173
Market Cap
837.26M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 135.16M | 43.79M | 47.92% |
Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PRTA News
- 2 days ago - Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights - Business Wire
- 5 days ago - Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm - GlobeNewsWire
- 9 days ago - Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 - Business Wire
- 7 weeks ago - Prothena Announces Board of Directors Update - Business Wire
- 2 months ago - Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease - Business Wire
- 3 months ago - Prothena Reports Third Quarter 2024 Financial Results and Business Highlights - Business Wire
- 3 months ago - Prothena to Report Third Quarter 2024 Financial Results on November 12 - Business Wire